Ionomycin SIGMA

PreclinicalSmall molecule

IInstituto Valenciano de Infertilidad, IVI VALENCIA

Ionomycin SIGMA is one of 52 small molecule programs targeting Efficacy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EfficacyRecruiting

EfficacyPreclinical

Recruiting

Competition

Competitive Landscape

139 competitors in Efficacy

#DrugCompanyPhaseTrials

Biaxin

AbbVie

Phase 3

4 2

Rayos

RRoxane Laboratories

Phase 3

5 3

Paraplatin

AAvyxa

Phase 3

4 4

Lesinurad

EEsperion Therapeutics, Inc.

Phase 3

2 5

Insulin 320

Novo Nordisk

Phase 3

5 6

Endothelin Receptor Antagonist

RRadboud University Medical Center

Phase 3

1 7

Sepofarsen

PProQR Therapeutics

Phase 3

1 8

Veracept

SSebela Women's Health Inc.

Phase 3

1 9

Cetaphil

GGalderma R&D

Phase 3

1 10

Aralen

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Efficacy1 trial

Efficacy of Oocyte Activation With Two Types of Ca2+ Ionophore.

Recruiting·IInstituto Valenciano de Infertilidad, IVI VALENCIA·N/A·NCT06106412·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ionomycin SIGMA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ionomycin SIGMA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ionomycin SIGMA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Instituto Valenciano de Infertilidad, IVI VALENCIA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IInstituto Valenciano de Infertilidad, IVI VALENCIA

Ionomycin SIGMA

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Efficacy1 trial

References

Drug Info

Quick Facts

Related News